Market Overview

ACADIA Pharma Shares Move Higher as JMP Boosted Price Target from $16 to $27

Share:
Related ACAD
Benzinga's Top Initiations
Acadia Will Outperform, Worth $48/Share Says Leerink
Next Week In Biotech: Earnings Deluge - From GSK And Achillion To Intercept And Vivus (Seeking Alpha)

JMP Securities maintains ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) with a Market Outperform and raises the price target from $16.00 to $27.00.

The stock has opened up more than 4 percent higher. With the stock last trading at $19.45, the firm's new price target implies potential upside of about 39 percent.

Latest Ratings for ACAD

DateFirmActionFromTo
Apr 2015Leerink SwannInitiates Coverage onOutperform
Mar 2015JefferiesMaintainsBuy
Feb 2015JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for ACAD
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings

 

Related Articles (ACAD)

Around the Web, We're Loving...